ES2071306T3 - El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas. - Google Patents

El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas.

Info

Publication number
ES2071306T3
ES2071306T3 ES91907436T ES91907436T ES2071306T3 ES 2071306 T3 ES2071306 T3 ES 2071306T3 ES 91907436 T ES91907436 T ES 91907436T ES 91907436 T ES91907436 T ES 91907436T ES 2071306 T3 ES2071306 T3 ES 2071306T3
Authority
ES
Spain
Prior art keywords
preparation
spray formulations
fluorinated surfactants
soluble fluorinated
dosage spray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907436T
Other languages
English (en)
Inventor
Robert K Schultz
Stephen N Quessy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Application granted granted Critical
Publication of ES2071306T3 publication Critical patent/ES2071306T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBEN FORMULACIONES EN AEROSOL DE SUSPENSIONES FARMACEUTICAS EN LAS QUE SE UTILIZA/N UNO O MAS ACIDOS CARBOXILICOS PERFLUORADOS O SUS ESTERES COMO AGENTES DISPERSANTES ACTIVOS EN LA SUPERFICIE Y 1,1,12
ES91907436T 1990-03-23 1991-03-22 El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas. Expired - Lifetime ES2071306T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49833390A 1990-03-23 1990-03-23

Publications (1)

Publication Number Publication Date
ES2071306T3 true ES2071306T3 (es) 1995-06-16

Family

ID=23980625

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907436T Expired - Lifetime ES2071306T3 (es) 1990-03-23 1991-03-22 El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas.

Country Status (7)

Country Link
EP (3) EP0636362B1 (es)
JP (1) JPH05505824A (es)
AU (1) AU654813B2 (es)
CA (1) CA2077354A1 (es)
DE (3) DE69131867T2 (es)
ES (1) ES2071306T3 (es)
WO (1) WO1991014422A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
PT98105B (pt) * 1990-06-28 1998-11-30 Glaxo Inc Processo para a preparacao de formulacoes em aerossol contendo como propulsor 1,1,1,2-tetrafluoroetano
US5785952A (en) * 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
US5474759A (en) * 1991-06-10 1995-12-12 Schering Corporation Non-chlorofluorocarbon aerosol formulations
ES2180592T3 (es) * 1991-06-10 2003-02-16 Schering Corp Formulaciones en aerosol libres de clorofluorocarbonos.
DE4123663A1 (de) * 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
DE69205177T2 (de) * 1991-12-12 1996-03-21 Glaxo Group Ltd., Greenford, Middlesex Pharmazeutische Aerosolformulierung.
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
DE69227257T2 (de) 1991-12-12 1999-03-25 Glaxo Group Ltd Arzneimittel
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US5376359A (en) * 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
MX9304585A (es) 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
US6042811A (en) * 1993-03-17 2000-03-28 3M Innovative Properties Company Aerosol formulation containing a diol-diacid derived dispersing aid
AU679511B2 (en) * 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
DE69424181T2 (de) * 1993-12-20 2000-10-19 Minnesota Mining And Mfg. Co., Saint Paul Flunisolide aerosolformulierungen
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
CN1088580C (zh) 1994-12-22 2002-08-07 阿斯特拉公司 气溶胶药物制剂
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5874469A (en) * 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
GB9805938D0 (en) 1998-03-19 1998-05-13 Glaxo Group Ltd Valve for aerosol container
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US7207330B1 (en) 1999-06-05 2007-04-24 Innovata Biomed Limited Delivery system
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
US6451287B1 (en) 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
WO2002024623A2 (en) 2000-09-22 2002-03-28 Glaxo Group Limited Novel alkanoic acid derivatives
KR100881258B1 (ko) 2000-12-22 2009-02-05 글락소 그룹 리미티드 살메테롤 지나포에이트를 위한 정량식 흡입기
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
HUP0401194A2 (hu) * 2001-08-03 2004-11-29 Glaxo Group Limited Új felületaktív anyagok, ezeket tartalmazó aeroszol készítmények és alkalmazásuk
GB0125127D0 (en) 2001-10-19 2001-12-12 Glaxo Group Ltd Compounds
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
MXPA04007899A (es) * 2002-02-13 2004-10-15 Glaxo Group Ltd Compuestos de acido carboxilico para usarse como agentes tensoactivos.
GB0205327D0 (en) 2002-03-06 2002-04-17 Glaxo Group Ltd compounds
US7185651B2 (en) 2002-06-18 2007-03-06 Nektar Therapeutics Flow regulator for aerosol drug delivery and methods
CA2528479A1 (en) 2003-06-13 2004-12-23 Altana Pharma Ag Formoterol and ciclesonide combination
US7589234B2 (en) 2003-07-02 2009-09-15 Daikin Industries, Ltd. Fluoroalkyl carboxylic acid derivative, method for producing fluorine-containing polymer, and aqueous dispersion of fluorine-containing polymer
EP2275479A1 (en) 2003-08-11 2011-01-19 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
US20080190418A1 (en) 2003-08-29 2008-08-14 Glaxo Group Limited Pharmaceutical Metered Dose Inhaler and Methods Relating Thereto
PL1670482T5 (pl) 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
CA2562386C (en) 2004-04-21 2014-11-18 Innovata Biomed Limited Inhaler
CA2677838C (en) 2007-02-11 2017-08-01 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
JP2012514586A (ja) 2009-01-05 2012-06-28 フラウンホーファーゲゼルシャフト ツール フォルデルング デル アンゲヴァンテン フォルシユング エー．フアー． Ｉｌ−２１およびｉｌ−２１変異体に基づく抗体欠乏性疾患を治療するための手段および方法
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
EP2575864A1 (en) 2010-06-04 2013-04-10 Trifoilium ApS Trefoil factors (tff) for the treatment of chronic pulmonary diseases
CN103221039A (zh) 2010-09-09 2013-07-24 三叶草私人有限公司 血管生成抑制剂的气道给药
US20140113877A1 (en) 2011-06-15 2014-04-24 Takeda Gmbh Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds
WO2012171900A1 (en) 2011-06-17 2012-12-20 Nycomed Gmbh Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
WO2018069210A1 (en) 2016-10-10 2018-04-19 Takeda Gmbh Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3250808A (en) * 1963-10-31 1966-05-10 Du Pont Fluorocarbon ethers derived from hexafluoropropylene epoxide
US4044126A (en) * 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
JPS5331582A (en) * 1976-09-04 1978-03-24 Daikin Ind Ltd Aerosol composition
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol

Also Published As

Publication number Publication date
EP0636362A3 (en) 1995-12-27
WO1991014422A1 (en) 1991-10-03
DE69109284T2 (de) 1995-08-24
CA2077354A1 (en) 1991-09-24
EP0636362B1 (en) 1999-12-22
EP0965335B1 (en) 2003-09-17
EP0636362A2 (en) 1995-02-01
EP0526481A1 (en) 1993-02-10
DE69131867T2 (de) 2000-05-18
JPH05505824A (ja) 1993-08-26
AU7668691A (en) 1991-10-21
DE69131867D1 (de) 2000-01-27
DE69133314D1 (de) 2003-10-23
EP0965335A1 (en) 1999-12-22
DE69109284D1 (de) 1995-06-01
AU654813B2 (en) 1994-11-24
EP0526481B1 (en) 1995-04-26

Similar Documents

Publication Publication Date Title
ES2071306T3 (es) El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas.
ES2084360T3 (es) Formulaciones de aerosoles exentas de clorofluorocarbonos.
ES2118835T3 (es) 2-etil-1h-imidazo(4,5-c)quinolin-4-aminas antiviricas.
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2080739T3 (es) Nitro-compuestos insecticidamente activos.
ES2186667T3 (es) Analogos de nucleosidos de 1,3-oxatiolano.
ITFI930247A1 (it) Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
ES2153820T3 (es) Derivados de benzimidazol, procedimiento para su preparacion y aplicaciones.
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
BR0212434A (pt) Dispositivos médicos contendo análogos de rapamicina
ATE355269T1 (de) Phenylalaninderivate
BR9202675A (pt) Processo e aparelho para distribuir um material polente cosmeticamente ativo para o corpo,composicao eletrostaticamente pulverizavel,e.uso de uma pulverizacao eletrostatica
MX9205046A (es) 1h-imidazo-(4,5-c)quinolin-4-aminas 1-substituidas
MX9300014A (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.
ES2045470T3 (es) Formulaciones medicinales en aerosol.
YU59192A (sh) Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja
PT98105A (pt) Processo para a preparacao de formulacoes em aerossol contendo como propulsor 1,1,1,2-tetrafluoroetano
ES2078551T3 (es) Medicamentos en aerosol.
PT918507E (pt) Formulacoes em aerossol
DK0582239T3 (da) Farmaceutisk og/eller kosmetisk formulering
CO5001019A1 (es) Composicion emulsionable para la represion de insectos, que se deriva del tipo de fenilpirazoles sustituidos en posi- cion 1, y no favorecen la formacion de cristales
ES2101230T3 (es) Nuevos derivados de sustancias anti-inflamatorias, analgesicas y/o antipireticas no estereoideas, su uso y formulaciones farmaceuticas que las contienen.
ES2093782T3 (es) Piridazindionas y su uso en el tratamiento de trastornos neurologicos.
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 526481

Country of ref document: ES